European journal of cancer (Oxford, England : 1990) · 2026
Real-life efficacy and tolerance of trametinib in BRAF-rearranged low-grade gliomas: A multicenter study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khouri Celine, Bibollet Amandine, Bouchoucha Yassine, Combarel David, Delahousse Julia, Aerts Isabelle, Bourdeaut Franck, Tauziede-Espariat Arnault, Metais Alice, Varlet Pascale, Beccaria Kevin, Blauwblomme Thomas, Guida Lelio, Benichi Sandro, Kariyawasam Dulanjalee, Dangouloff-Ros Volodia, Boddaert Nathalie, Sellami Noura, Dufour Christelle, Simbozel Marie, Guerrini-Rousseau Lea, Geoerger Birgit, Grill Jacques, Leblond Pierre, Abbou Samuel
Аннотация
BACKGROUND: MEK inhibition has demonstrated activity in pediatric low-grade gliomas (pLGGs) driven by BRAF rearrangements, but data on trametinib remain limited, regarding efficacy, short and long-term toxicities.
METHODS: We conducted a retrospective multicenter study of patients with BRAF-rearranged non NF1 pLGGs receiving trametinib across three French pediatric oncology centers. Plasma concentrations were monitored.
RESULTS: Between 2015 and 2023, 46 patients had a median age of 8.7 years (range 1.2-18.6). Trametinib achieved a radiological disease control rate of 78% (36/46), including 65% partial or minor responses and 13% stable disease, with activity even in heavily pretreated (up to 6 lines) and chemotherapy-refractory tumors. Clinical improvement occurred in 72% of patients. Median treatment duration was 14.2 months (range, 1.0-55.1). Among 35 patients who discontinued treatment, 37% remained treatment-free after a median follow-up of 16.1 months (4.3-44.2). Grade 3 treatment-related adverse events occurred in one-third of patients. Common toxicities included cutaneous events (69%), paronychia (64%), gastrointestinal symptoms (51%), elevated creatine kinase (54%) and transaminases (31%). Ophthalmologic (16%) toxicities and epistaxis (17%) of which 35% were grade 2 and required intervention, were observed. Body mass index Z-score increased during treatment but was clinically significant (≥1 SD) and related to trametinib in only 17% of patients. Pharmacokinetics showed high interpatient variability, with no correlation between plasma concentrations and efficacy or toxicity.
CONCLUSION: Trametinib demonstrates sustained activity in BRAF-rearranged pLGGs, including in heavily pretreated patients. This study represents the largest reported cohort of BRAF-rearranged pLGGs, expanding prior evidence and supporting a class effect of MEK inhibitors.
METHODS: We conducted a retrospective multicenter study of patients with BRAF-rearranged non NF1 pLGGs receiving trametinib across three French pediatric oncology centers. Plasma concentrations were monitored.
RESULTS: Between 2015 and 2023, 46 patients had a median age of 8.7 years (range 1.2-18.6). Trametinib achieved a radiological disease control rate of 78% (36/46), including 65% partial or minor responses and 13% stable disease, with activity even in heavily pretreated (up to 6 lines) and chemotherapy-refractory tumors. Clinical improvement occurred in 72% of patients. Median treatment duration was 14.2 months (range, 1.0-55.1). Among 35 patients who discontinued treatment, 37% remained treatment-free after a median follow-up of 16.1 months (4.3-44.2). Grade 3 treatment-related adverse events occurred in one-third of patients. Common toxicities included cutaneous events (69%), paronychia (64%), gastrointestinal symptoms (51%), elevated creatine kinase (54%) and transaminases (31%). Ophthalmologic (16%) toxicities and epistaxis (17%) of which 35% were grade 2 and required intervention, were observed. Body mass index Z-score increased during treatment but was clinically significant (≥1 SD) and related to trametinib in only 17% of patients. Pharmacokinetics showed high interpatient variability, with no correlation between plasma concentrations and efficacy or toxicity.
CONCLUSION: Trametinib demonstrates sustained activity in BRAF-rearranged pLGGs, including in heavily pretreated patients. This study represents the largest reported cohort of BRAF-rearranged pLGGs, expanding prior evidence and supporting a class effect of MEK inhibitors.